// App-Quantinova.ai

FRI0332 : EVALUATION OF THE INDIVIDUAL COMPONENTS OF ACR50+PASI100 AND MDA AT WEEK 24 FROM THE SPIRIT-H2H TRIAL COMPARING THE EFFICACY AND SAFETY OF IXE VERSUS ADA IN PATIENTS WITH PSA NAÏVE TO BDMARDS

Researchers

Presenter

  • L. C. Coates

Principal Investigators

  • M. Nissen

  • C. El Baou

  • J. Zochling

  • A. Marchesoni

  • S. Liu Leage

  • E. Soriano

  • V. F. Azevedo

  • K. Machold

  • C. Sapin

Medical Centers

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • University of Geneva, Division of Rheumatology, Geneva, Switzerland

  • Eli Lilly Research and Development, Windlesham, United Kingdom

  • Rheumatology Tasmania, Hobart, Australia

  • ASST Gaetano Pini-CTO Polo Isocrate, Milano, Italy

  • Eli Lilly and Company, Indianapolis, United States of America

  • Hospital Aleman de Buenos Aires, Buenos Aires, Argentina

  • Federal University of Parana, Curitiba, Brazil

  • Medical University of Vienna, Vienna, Austria

Locations

  • United Kingdom

  • Switzerland

  • Australia

  • Italy

  • United States

  • Argentina

  • Brazil

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

Disease

  • Psoriasis

Biomarkers

  • Prostate specific antigen

  • Malondialdehyde

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved